Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-15 4:55 pm Unchanged | 2025-03-31 | 13G | Dianthus Therapeutics, Inc. DNTH | RA CAPITAL MANAGEMENT L.P. | 2,866,733 8.900% | 0 (Unchanged) | Filing History |
| 2025-05-15 4:34 pm Unchanged | 2025-03-31 | 13G | Dianthus Therapeutics, Inc. DNTH | TCG Crossover GP II, LLC | 1,501,624 4.700% | 0 (Unchanged) | Filing History |
| 2025-05-15 4:14 pm Purchase | 2025-03-31 | 13G | Dianthus Therapeutics, Inc. DNTH | Vestal Point Capital LP | 1,700,069 5.300% | 1,700,069 (New Position) | Filing History |
| 2025-05-12 10:28 am Purchase | 2025-03-31 | 13G | Dianthus Therapeutics, Inc. DNTH | FMR LLC | 4,482,609 14.000% | 2,264,397 (+102.08%) | Filing History |
| 2025-04-24 2:17 pm Sale | 2025-03-31 | 13G | Dianthus Therapeutics, Inc. DNTH | BlackRock Inc. BLK | 1,600,153 5.000% | -44,666 (-2.72%) | Filing History |
| 2025-04-17 4:10 pm Purchase | 2025-04-10 | 13G | Dianthus Therapeutics, Inc. DNTH | Point72 Asset Management L.P. | 1,894,304 5.900% | 1,894,304 (New Position) | Filing History |
| 2025-03-24 4:08 pm Purchase | 2025-03-17 | 13G | Dianthus Therapeutics, Inc. DNTH | Deep Track Capital LP | 2,357,702 7.340% | 2,357,702 (New Position) | Filing History |
| 2025-03-19 9:30 pm Purchase | 2025-03-17 | 13D | Dianthus Therapeutics, Inc. DNTH | Avidity Partners Management LP | 3,378,939 9.900% | 448,689 (+15.31%) | Filing History |
| 2025-02-14 6:32 pm Sale | 2024-12-31 | 13G | Dianthus Therapeutics, Inc. DNTH | RA CAPITAL MANAGEMENT L.P. | 2,866,733 9.400% | -128,290 (-4.28%) | Filing History |
| 2025-02-14 07:54 am Sale | 2024-12-31 | 13G | Dianthus Therapeutics, Inc. DNTH | BCLS Fund III Investments, LP | 2,689,707 8.800% | -302,321 (-10.10%) | Filing History |
| 2025-02-05 5:42 pm Purchase | 2024-12-31 | 13G | Dianthus Therapeutics, Inc. DNTH | Octagon Capital Advisors LP | 2,110,167 7.100% | 363,500 (+20.81%) | Filing History |
| 2024-12-03 9:19 pm Purchase | 2024-11-29 | 13D | Dianthus Therapeutics, Inc. DNTH | Avidity Partners Management LP | 2,930,250 9.900% | 7,427 (+0.25%) | Filing History |
| 2024-11-22 4:41 pm Purchase | 2024-11-15 | 13G | Dianthus Therapeutics, Inc. DNTH | TCG Crossover GP II, LLC | 1,501,624 5.100% | 1,501,624 (New Position) | Filing History |
| 2024-11-14 5:48 pm Sale | 2024-09-30 | 13G | Dianthus Therapeutics, Inc. DNTH | 5AM Partners VII, LLC | 1,027,711 3.500% | -654,873 (-38.92%) | Filing History |
| 2024-11-14 5:47 pm Purchase | 2024-09-30 | 13G | Dianthus Therapeutics, Inc. DNTH | Venrock Healthcare Capital Partners III, L.P. | 1,744,373 5.900% | 816,667 (+88.03%) | Filing History |
| 2024-11-08 5:31 pm Unchanged | 2024-09-30 | 13G | Dianthus Therapeutics, Inc. DNTH | BlackRock Inc. BLK | 1,644,819 5.600% | 0 (Unchanged) | Filing History |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | Dianthus Therapeutics, Inc. DNTH | BlackRock Inc. BLK | 1,644,819 5.600% | 1,644,819 (New Position) | Filing History |
| 2024-10-11 4:02 pm Purchase | 2024-09-30 | 13G | Dianthus Therapeutics, Inc. DNTH | Octagon Capital Advisors LP | 1,746,667 6.000% | 1,746,667 (New Position) | Filing History |
| 2024-09-12 8:45 pm Unchanged | 2024-03-21 | 13D | Dianthus Therapeutics, Inc. DNTH | Viridian LLC | 1,090,283 3.720% | 0 (Unchanged) | Filing History |
| 2024-04-01 6:34 pm Sale | 2024-04-01 | 13D | Dianthus Therapeutics, Inc. DNTH | Fairmount Funds Management LLC | 2,957,385 9.990% | -3,362 (-0.11%) | Filing History |